Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The list of benefits for Novo Nordisk's semaglutide keeps getting longer. Now, it seems the GLP-1 agonist could help patients with heart failure, adding to earlier studies showing it can treat ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...